Lisa Rojkjaer - Nov 25, 2021 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
Chief Medical Officer
Signature
/s/ Michael Mueller, as Attorney-in-Fact
Stock symbol
VIRX
Transactions as of
Nov 25, 2021
Transactions value $
-$21,847
Form type
4
Date filed
11/29/2021, 06:50 PM
Previous filing
May 13, 2021
Next filing
Mar 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIRX Common Stock Options Exercise $0 +8.25K +23.75% $0.00 43K Nov 25, 2021 Direct F1
transaction VIRX Common Stock Sale -$9.36K -1.95K -4.53% $4.80 41.1K Nov 26, 2021 Direct F2, F3
transaction VIRX Common Stock Sale -$12.5K -2.59K -6.31% $4.82 38.5K Nov 29, 2021 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Restricted Stock Units Options Exercise $0 -8.25K -12.5% $0.00 57.8K Nov 25, 2021 Common Stock 8.25K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
F2 The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
F3 Represents the weighted average share price of an aggregate total of 1,950 shares sold in the price range of $4.7150 to $5.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Represents the weighted average share price of an aggregate total of 2,591 shares sold in the price range of $4.62 to $5.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.